跳至主要内容
临床试验/NCT07666113
NCT07666113招募中不适用

The Diagnostic Validity and Clinical Impact of Blood-based Biomarkers for the Diagnosis of Alzheimer's Disease at the Primary Care Level.

Universitaire Ziekenhuizen KU Leuven1 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2026年5月26日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
240
试验地点
1

研究概览

简要总结

The goal of this study is to determine how blood biomarker tests (ptau217 and ptau217/Aβ42) performed in primary care influence the patient trajectory in individuals with cognitive concerns.

Participants will provide a blood sample for biomarker testing and undergo clinical assessments as part of diagnostic evaluation.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
55 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients between 55 and 85 years old who consult their PCP due to concerns about their cognitive status.

排除标准

  • Comorbidities that would interfere with study cooperation or interpretability of study results (for instance substance abuse or cardiac, renal or hepatic failure).
  • Concomitant medications that would interfere with cognitive assessments.
  • A prior diagnosis of AD and related disorders or other neurodegenerative disease.

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验